{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Robert", "organization": "", "rank": 1, "lastname": "CYRAN"}], "original": "By ROBERT CYRAN"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [], "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "Mylan\u2019s New Deal May Not Be the One Shareholders Wanted"}, "print_page": null, "keywords": [{"value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Mylan Inc", "is_major": "N", "rank": "2", "name": "organizations"}, {"value": "Meda AB", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "Perrigo Company", "is_major": "N", "rank": "4", "name": "organizations"}, {"value": "Teva Pharmaceutical Industries Ltd", "is_major": "N", "rank": "5", "name": "organizations"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "6", "name": "subject"}], "snippet": "The drug maker Mylan, which rejected one offer and was itself rebuffed on another, may be overpaying for the Swedish company Meda.", "source": "The New York Times", "lead_paragraph": "The drug maker Mylan, which rejected one offer and was itself rebuffed on another, may be overpaying for the Swedish company Meda.", "word_count": "343", "pub_date": "2016-02-12T00:00:00Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/02/12/business/dealbook/mylans-new-deal-may-not-be-the-one-shareholders-wanted.html", "_id": "56bce0f738f0d810e6a1a1c3"}